Titan Receives Promising Results from Phase III Trial for Opioid Addiction

Titan Pharmaceuticals saw positive data in its Phase III clinical trial of Probuphine for the treatment of opioid addiction.

The randomized, double-blind, placebo-controlled, multicenter trial demonstrated significant reduction of illicit opioid use over 16 weeks compared with placebo. This change was measured by urine testing performed three times per week, Titan said.

Probuphine is a subcutaneous implant formulation that was developed using the company’s ProNeura technology. It is typically placed in a patient’s upper arm with a small, solid rod made from a mixture of ethylene-vinyl acetate and a drug substance. Once inserted, the system delivers six months of buprenorphine, an approved agent used for treating opioid addiction.